As the major excitatory neurotransmitter in the mammalian CNS, glutamate is essential for synaptic transmission; however, excessive neuronal stimulation by glutamate (known as excitotoxicity) can induce neuronal damage and even death (Maragakis and Rothstein 2001) . Therefore, as a potential neurotoxin, clearance of glutamate from the synapse may be critical for neuronal survival. Cellular uptake by glutamate transport (GT) is the primary mechanism in maintaining synaptic glutamate concentrations (Anderson and Swanson 2000) , which is primarily mediated by astrocytes . Pharmacological inhibition of GT leads to neurodegeneration and death (Robinson et al. 1993; Rothstein et al. 1993; Lievens et al. 2000) , consistent with a role for impaired GT in excitotoxicity.
Excitotoxic mechanisms of cell death have been implicated in several neurodegenerative disorders, such as stroke, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD), although evidence is lacking in many instances (Maragakis and Rothstein 2001) . Glutamate transport is inhibited in AD brain (Masliah et al. 1996) through an as yet unknown mechanism. Oxidative damage is elevated in the AD brain (Markesbery 1997) , whereas oxidation of proteins (e.g. transporters) is known to decrease their activity (Volterra et al. 1994; Keller et al. 1997a,b; Blanc et al. 1998) . The correlation of these two pathological features could possibly provide an understanding of the mechanisms underlying neurodegeneration in AD.
Alzheimer's disease is characterized by the deposition of the beta-amyloid peptide (Ab) , that may play a role in the pathogenesis of the disorder (Selkoe 1996) . Ab1±42 induces oxidative damage to neural proteins and lipids in vitro, which can be inhibited by antioxidants , and is thought to mediate the oxidative damage present in AD brain Varadarajan et al. 2001) . Lipid oxidation by Ab (Butter®eld et al. 1994) can result in the formation of 4-hydroxy-2-nonenal (HNE), which is suggested to play a major role in the toxicity of Ab (Mark et al. 1997) . In particular, the addition of either Ab or HNE to cells or synaptosomes results in the inhibition of GT (Harris et al. 1996; Keller et al. 1997a,b) . Thus, we hypothesized that decreased GT in the brain in AD may result from covalent modi®cation by HNE of the glial glutamate transporter GLT-1 (EAAT2). Furthermore, we investigated whether the addition of Ab1±42, the predominant form of this peptide in AD, to synaptosomes would lead to modi®cation of GLT-1 by HNE. Both studies lead to results that may explain the inhibition of GT in AD and may provide some evidence for excitotoxic neurodegeneration in AD.
Experimental procedures

Materials
For the treatment of synaptosomes, HNE was purchased from Cayman Chemical and Ab1±42 was purchased from Anaspec. Nonidet P-40 was purchased from Roche Diagnostics and protease inhibitors were from ICN. The anti-HNE antibody was a generous gift from Dr Szweda and was prepared and characterized as described previously (Uchida et al. 1993) . For the development of western blots, anti-GLT-1 (guinea pig) and peroxidaseconjugated 28IgG (goat anti-guinea pig) antibodies were purchased from Chemicon, and ECL, a chemiluminescent substrate for peroxidase, was obtained from Pharmacia. All other reagents were purchased from Sigma.
Brain tissue sampling
Inferior parietal lobule (IPL) tissue samples used for analyses were taken at autopsy from seven AD and four control subjects, immediately frozen in liquid nitrogen, and stored at 2 808C. The Rapid Autopsy Program of the University of Kentucky Alzheimer's Disease Research Center resulted in extremely short post mortem intervals (PMIs). Demographic data for the patients are presented in Table 1 . All AD subjects displayed progressive intellectual decline and met NINCDS-ADRDA Workgroup criteria for the clinical diagnosis of probable AD (McKhann et al. 1984) . All AD subjects met accepted guidelines for the histopathologic diagnosis of AD (National Institute on Aging and the Reagan Institute Working Group 1997). Hematoxylin-eosin and modi®ed Bielschowsky staining and the 10-D-5 immunohistochemical reaction were used on multiple neocortical, hippocampal, amygdala, brainstem and cerebellum sections for diagnosis. Some AD patients were also diagnosed with diffuse lewy bodies, and results were no different from AD patients with or without diffuse lewy bodies. Control subjects underwent annual neuropsychological testing as a part of our normal volunteer longitudinal aging study, and did not have a history of dementia or other neurological disorders. All control subjects had test scores in the normal range. Neuropathologic evaluation of control brains revealed only age-associated gross and histopathologic alterations.
Synaptosomal preparation and treatment
Rat cortical synaptosomes were prepared by ultracentrifugation on discontinuous sucrose gradients as described previously . Protein concentrations were determined by the Pierce BCA method and adjusted to a concentration of 8 mg/mL. Synaptosomes were treated with 10 mm of either HNE or Ab1±42 for 4 h at 378C, washed with phosphate-buffered saline (PBS) and aliquoted for immunoprecipitation. Ab1±42 was dissolved in PBS at a concentration of 1 mg/2 mL, and preincubated for 24 h at 378C prior to treatment of synaptosomes.
Immunoprecipitation and western blotting
Immunoprecipitation (IP) was performed essentially as described previously (Keller et al. 1997a) . Synaptosomes or tissue samples from the IPL of AD or control brains were brie¯y sonicated in a modi®ed RIPA buffer (1% Nonidet P-40, 50 mm Tris, 150 mm NaCl, 2 mm EDTA, 5 mg/mL leupeptin, 5 mg/mL aprotinin, 2 mg/mL pepstatin, 0.25 mm phenylmethylsulfonyl uoride, 10% glycerol, pH 7.6), and solublized for 4 h at 48C. Lysates were centrifuged, protein concentrations determined on the soluble fraction, and 500 mg total soluble protein aliquoted for each sample. A rabbit polyclonal antibody (5 mL) raised against covalent HNE-protein Michael adducts (Uchida et al. 1993) was added directly to the lysates, forming complexes with all HNE-immunoreactive proteins. Antibody/lysate solutions were incubated on a rotary mixer overnight at 48C. HNE-protein/ antibody complexes were precipitated with protein A-conjugated acrylic beads. Protein A beads were added in 50 mL aliquots from a stock of 300 mg/mL in PBS and mixed on a rotary mixer for 6 h at 48C. Beads were then centrifuged and washed three times with the modi®ed RIPA buffer and immunoprecipitates were resuspended in Laemmli sample buffer. The GLT-1 immunoreactivity among HNE-immunoprecipitated proteins was analyzed by western blotting on a 15% polyacrylamide gel. After transfer to nitrocellulose, blots were blocked with 3% bovine serum albumin, probed with anti-GLT-1 (1 : 3000; overnight at 48C), and developed with a horseradish peroxidase-conjugated secondary antibody and a chemiluminescent substrate. The anti-GLT-1 was raised against a peptide corresponding to its 20 C-terminal amino acids, which are of identical sequence in rat and human. Untreated lysates were run on western blots as a positive control for GLT-1 immunoreactivity.
Results and Discussion
Glutamate transporters function by removing synaptically released glutamate, a potential neurotoxin. Inhibition of this function results in neurodegeneration and death (Robinson et al. 1993; Rothstein et al. 1993; Lievens et al. 2000) . Because GT is inhibited in cells and synaptosomes after treatment with Ab, HNE or other reagents that can induce lipid oxidation (Volterra et al. 1994; Harris et al. 1996; Trotti et al. 1996; Keller et al. 1997a,b; Blanc et al. 1998) , the role of HNE in this process was investigated. Also, because Ab induces lipid peroxidation (Butter®eld et al. 1994 ) and HNE formation (Mark et al. 1997) , we analyzed a possible mechanism by which Ab1±42 could decrease GT. Synaptosomes were treated with 10 mm of either HNE or Ab for 4 h at 378C or remained untreated. Following IP of HNE-modi®ed proteins from the synaptosomes, western blots probed with anti-GLT-1 indicate increased immunoreactivity in samples treated with both HNE and Ab (Fig. 1b) . In comparison with untreated control samples, GLT-1 is modi®ed by HNE to a greater extent in treated synaptosomes (i.e. greater HNE immunoreactivity), and is therefore immunoprecipitated to a greater extent from treated synaptosomes (i.e. greater GLT-1 immunoreactivity on western blots). Interestingly, equimolar concentrations of HNE and Ab were incubated with synaptosomes; however, addition of HNE does not modify GLT-1 to the extent that Ab does. This might indicate a catalytic effect by Ab in oxidizing lipids, or simply that exogenously added HNE might react with a number of aqueous soluble proteins before diffusing to the membrane-bound glutamate transporter. After insertion into the membrane bilayer, Ab oxidizes lipids (Butter®eld et al. 1994) , and HNE thus generated could react more rapidly with membranebound proteins such as the transmembrane protein, GLT-1.
Our data are consistent with previous reports of HNE modi®ca-tion of GLT-1. The HNE binds to an immunoprecipitated GLT-1 in solution as well as in cultured cortical astrocytes and synaptosomes (Keller et al. 1997a; Blanc et al. 1998) . As an electrophilic aldehyde, HNE reacts covalently with cysteine, lysine and histidine residues of proteins, disrupts their structure, and alters their function (Esterbauer et al. 1991; Subramaniam et al. 1997) . The activities of both neuronal and glial GT proteins (e.g. GLT-1) are regulated by a thiol-based redox mechanism (Trotti et al. 1997) , suggesting that HNE binding may play a role in disrupting the function of these proteins. The ability of Ab1±42 treatment to oxidatively modify GLT-1 is particularly relevant to AD, where the 42-amino acid variant of Ab is hypothesized to play a causative role (Selkoe 1996; Varadarajan et al. 2001) . Although it is known that GT is inhibited in the AD brain (Masliah et al. 1996) , the mechanism of this inhibition remains unknown. Levels of both free and protein-bound HNE are increased in AD (Markesbery and Lovell 1998; Montine et al. 1998) , and may be related to both Ab overproduction and GT inhibition. Accordingly, we analyzed HNE modi®cations to GLT-1 from the IPL of AD and control brains, and therefore a possible mechanism by which GT might be inhibited in the AD brain. The IPL region displays severe histopathologic alterations in AD that correlate to oxidative damage (Hensley et al. 1995) including elevated lipid peroxidation (Palmer and Burns 1994) . Western blot analysis of HNE-modi®ed proteins from IPL lysates results in increased GLT-1 immunoreactivity (Fig. 1a) , suggesting that GLT-1 is covalently modi®ed by HNE in this region of the AD brain. Based upon HNE-mediated inhibition of GT in models of AD, this suggests that HNE modi®cation of GLT-1 may contribute to decreased GT in the AD brain.
Much experimental evidence indicates the importance of glial GT proteins, especially GLT-1 (Anderson et al. 2000; Maragakis and Rothstein 2001) . Decreasing GT by knock-out or knock-down of GLT-1 protein, removal of astrocytes (and glial transporter such as GLT-1), or by using competitive inhibitors of GLT-1 increases neuronal sensitivity to glutamate and induces neurodegeneration and death (Rosenburg and Aizenman 1989; Robinson et al. 1993; Rothstein et al. 1993; Rothstein et al. 1996; Tanaka et al. 1997) . Similarly, HNE inhibition of GT, especially GLT-1, may induce excitotoxicity and neurodegeneration. Similar mechanisms have been explored that link oxidative damage to excitotoxicity in neurodegeneration (Trotti et al. 1998) , and existing evidence for such a mechanism is strongest in ALS (Ludolph et al. 2000) . Studies reveal decreased total GLT-1 protein and GT, and increased GLT-1 modi®cation by HNE in spinal cords from ALS patients Pedersen et al. 1998) . Further, riluzole, currently approved for use in ALS, is thought to prevent glutamate release (Maragakis and Rothstein 2001) . The current study, coupled with previous results implicating altered GT, suggests that similar mechanisms may also play a role in AD.
We demonstrate that GLT-1 is modi®ed by HNE in synaptosomes treated with Ab1±42 and in the IPL region of the AD brain. The possibility that Ab1±42 mediates decreased GT in vivo by generating HNE may unify multiple mechanisms of neurodegeneration in AD including altered amyloid precursor protein (APP) processing, oxidative damage, decreased GT, excitotoxicity and altered calcium homeostasis. Altered processing of APP not only results in Ab1±42 formation, but also results in decreased secretion of APPa. Normal proteolysis of APP results in the secretion of APPa, which protects against excitotoxic injuries (Mattson et al. 1993; Masliah et al. 1997) , stimulates glutamate transport (Masliah et al. 1997; Mattson et al. 1999; Masliah et al. 2000) , and regulates intracellular calcium levels (Mattson et al. 1993) . Thus, in AD, where there is an overproduction of Ab1±42 and a corresponding decrease in secreted APPa, generation of HNE by Ab at the synapse may lead to modi®cation of proteins critical for synaptic function, including GLT-1. This suggests that oxidative damage to lipids, and subsequent production of HNE, may ultimately lead to excitotoxicity, and may be an important mechanism in the neurodegeneration in AD. 
